Rediff Logo
Money
Line
Channels: Astrology | Broadband | Contests | E-cards | Money | Movies | Romance | Search | Women
Partner Channels: Bill Pay | Health | IT Education | Jobs | Travel
Line
Home > Money > Reuters > Report
August 29, 2001
Feedback  
  Money Matters

 -  Business Special
 -  Business Headlines
 -  Corporate Headlines
 -  Columns
 -  IPO Center
 -  Message Boards
 -  Mutual Funds
 -  Personal Finance
 -  Stocks
 -  Tutorials
 -  Search rediff

    
      



 
Reuters
 Search the Internet
         Tips
 Sites: Finance, Investment
E-Mail this report to a friend
Print this page

Cadila gets Philippines nod to sell products

Cadila Healthcare Ltd has got approval from the Philippines Bureau of Foods and Drugs to manufacture and sell several of its drugs in the Philippine market, a company statement said on Wednesday.

The BFAD certificate will allow Cadila to manufacture and export oral solids and oral liquids to the Philippines.

Cadila has already registered seven products with Philippine medical authorities and 16 more would be added to the list shortly, the statement said. "Seven more new molecule dossiers will be submitted by the end of September 2001," it said.

The statement said Cadila was in the process of tying up with a marketing oriented company in the Philippines to promote its products in the antibacterial, cardiovascular, pain management and anti-ulcerant segments.

The company said it was hopeful of clocking a turnover of $2 million from the Philippine market by 2003-04.

"Since BFAD regulations are patterned on the US Food and Drug Authority guidelines, the BFAD approval will help in fast track registration of Cadila products in other ASEAN countries," the statement said.

Back to top
(c) Copyright 2000 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Tell us what you think of this report

ADVERTISEMENT